Evidence map›Paper›PMID 40592881›Full record

ArticleNature communications2025

A contra-steric chemoselective hydrometallation strategy with bulky NHC for catalytic asymmetric branched allylamine synthesis.

Weihao Chen, Zhifeng Zhang, Chun-Yu Ho

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Weihao Chen *Guangdong Provincial Key Laboratory of Catalysis, Southern University of Science and Technology (SUSTech), Shenzhen, China.ORCID http://orcid.org/0000-0002-6709-9223
Zhifeng Zhang *Guangdong Provincial Key Laboratory of Catalysis, Southern University of Science and Technology (SUSTech), Shenzhen, China.ORCID http://orcid.org/0009-0000-9419-7278
Chun-Yu HoGuangdong Provincial Key Laboratory of Catalysis, Southern University of Science and Technology (SUSTech), Shenzhen, China. jasonhcy@sustech.edu.cn.ORCID http://orcid.org/0000-0002-1064-8682

Funding

National Natural Science Foundation of China (National Science Foundation of China) 22471116
6 · The paper itself

Abstract

Development of contra-steric alkene hydrometallation method is one of the keys in branched product synthesis, especially when a bulky ligand steric environment is essential at other stages of the catalytic cycle. This study presents our efforts in this regard with broad scope using N-heterocyclic carbene (NHC), and establishes a chiral (NHC)Ni(II)-catalyzed intermolecular cross-hydroalkenylation system of enamine (alkenyl-carbamate/phthalimide) and α-olefin for the synthesis of highly substituted branched allylamines. A sterically adaptable chiral NHC-Ni(II) catalyst design with an open quadrant enhances interaction with the heteroatom on enamine, offering a precise chemo-, regio-, and enantioselective insertion control throughout the process in a mixture of olefins and allowing convergent synthesis. Besides, α-olefin serves as both terminal and internal 2-alkenyl reagents, yielding a 1,2,3-substituted allylamine by regio- and E-selective isomerization of the 1,2-disubstituted allylamine. Overall, the success of this alkene-based strategy addresses the intrinsic problems associated with alkyne- and alkenyl halide reagent-based synthesis, demonstrates good versatility and scope, and addresses the shortcomings of conceivable approaches based on rigid and sterically bulky NHCs.

Identifiers

PMID40592881
PMCPMC12217769

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.